Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.30 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.30 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.30 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24456419 | 0.89 | KDM5B (0.36) | KDM5BCYP4F2CYP4A11FLT3ALDH1A1 | |
| SCHEMBL31488070 | 0.85 | FFAR1 (0.42) | KDM5BCYP4F2CYP4A11FLT3ALDH1A1 | |
| SCHEMBL760525 | 0.85 | FFAR1 (0.42) | KDM5BCYP4F2CYP4A11FLT3ALDH1A1 | |
| SCHEMBL31541173 | 0.80 | KDM5B (0.36) | KDM5BCYP4F2CYP4A11FLT3ALDH1A1 | |
| SCHEMBL17069527 | 0.80 | KDM5B (0.35) | KDM5BCYP4F2CYP4A11FLT3FGFR1 | |
| SCHEMBL1912961 | 0.79 | KDM5B (0.34) | KDM5BFLT3FGFR1FGFR2FGFR4 | |
| SCHEMBL31133152 | 0.78 | FFAR1 (0.37) | KDM5BFLT3FGFR1FGFR2FGFR4 | |
| SCHEMBL23699731 | 0.76 | FFAR1 (0.46) | — | |
| SCHEMBL20953116 | 0.76 | KDM5B (0.37) | KDM5BCYP4F2CYP4A11FLT3SYK | |
| SCHEMBL24031822 | 0.73 | CYP4F2 (0.41) | CYP4F2CYP4A11ALDH1A1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034187-A1 | STING AGONISTIC COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-01-30 | — | — | US | disclosed |
| US-12152049-B2 | STING agonistic compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-11-26 | — | — | US | disclosed |
| US-11919917-B2 | Sting agonistic compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-03-05 | — | — | US | disclosed |
| CN-112867721-B | STING agonistic compounds | 小野药品工业株式会社 | 2023-12-08 | — | — | CN | disclosed |
| US-20230339992-A1 | STING AGONISTIC COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-10-26 | — | — | US | disclosed |
| US-20230151024-A1 | STING AGONISTIC COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230141284-A1 | CANCER THERAPEUTIC METHOD | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-05-11 | — | — | US | disclosed |
| EP-4134134-A1 | STING AGONISTIC COMPOUND | ONO Pharmaceutical Co., Ltd. (JP) | 2023-02-15 | — | — | EP | disclosed |
| EP-4134098-A1 | METHOD OF CANCER THERAPY | ONO Pharmaceutical Co., Ltd. (JP) | 2023-02-15 | — | — | EP | disclosed |
| US-11365192-B2 | Pyridine compound substituted with azole | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2022-06-21 | — | — | US | disclosed |
| US-20210363166-A1 | STING AGONISTIC COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-11-25 | — | — | US | disclosed |
| US-11130773-B2 | STING agonistic compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-09-28 | — | — | US | disclosed |
| US-20210253615-A1 | STING AGONISTIC COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-08-19 | — | — | US | disclosed |
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2021-04-29 | — | — | US | disclosed |
| US-20210040062-A1 | AZOLE-SUBSTITUTED PYRIDINE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2021-02-11 | — | — | US | disclosed |
| EP-3666766-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | Taisho Pharmaceutical Co., Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
| EP-3418276-A1 | AZOLE-SUBSTITUTED PYRIDINE COMPOUND | Taisho Pharmaceutical Co., Ltd. (JP) | 2018-12-26 | — | — | EP | disclosed |
| US-9150592-B2 | Heterocyclic nuclear hormone receptor modulators | ABBVIE INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20140179676-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | ABBVIE INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20130217592-A1 | ARRAYS AND METHODS COMPRISING M. SMITHII GENE PRODUCTS | THE WASHINGTON UNIVERSITY (US) | 2013-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | CYP2C19, CYP4A11, CYP11B1 | KDM5B 126/4885CYP4F2 20/4885CYP4A11 2/4885 |
| US-20230141284-A1 | CANCER THERAPEUTIC METHOD | STING1, CGAS, IFNAR1 | KDM5B 3904/4885CYP4F2 2601/4885CYP4A11 138/4885 |
| US-20250034187-A1 | STING AGONISTIC COMPOUND | STING1, IRF3, MAVS | KDM5B 2866/4885CYP4F2 4797/4885CYP4A11 2525/4885 |
| US-20140179676-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | NR5A2, NR5A1, GPER1 | KDM5B 2717/4885CYP4F2 160/4885CYP4A11 58/4885 |
| US-11365192-B2 | Pyridine compound substituted with azole | CYP2C19, CYP4A11, CYP11B1 | KDM5B 126/4885CYP4F2 20/4885CYP4A11 2/4885 |
| US-20210363166-A1 | STING AGONISTIC COMPOUND | STING1, IRF3, MAVS | KDM5B 2866/4885CYP4F2 4797/4885CYP4A11 2525/4885 |
| US-11130773-B2 | STING agonistic compound | STING1, IRF3, MAVS | KDM5B 2866/4885CYP4F2 4797/4885CYP4A11 2525/4885 |
| US-20230151024-A1 | STING AGONISTIC COMPOUND | STING1, CGAS, TLR1 | KDM5B 2742/4885CYP4F2 4724/4885CYP4A11 1930/4885 |
| US-12152049-B2 | STING agonistic compound | STING1, IRF3, MAVS | KDM5B 2866/4885CYP4F2 4797/4885CYP4A11 2525/4885 |
| US-20210040062-A1 | AZOLE-SUBSTITUTED PYRIDINE COMPOUND | CYP2F1, CYP21A2, CYP11B1 | KDM5B 147/4885CYP4F2 8/4885CYP4A11 13/4885 |
| US-11919917-B2 | Sting agonistic compound | STING1, IRF3, MAVS | KDM5B 2866/4885CYP4F2 4797/4885CYP4A11 2525/4885 |
| US-20210253615-A1 | STING AGONISTIC COMPOUND | STING1, IRF3, MAVS | KDM5B 2866/4885CYP4F2 4797/4885CYP4A11 2525/4885 |
| US-20230339992-A1 | STING AGONISTIC COMPOUND | STING1, IRF3, MAVS | KDM5B 2866/4885CYP4F2 4797/4885CYP4A11 2525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.